person · Reporting owner

Albers Jeffrey W.

Disclosed activity across 4 companies

Tapewire entity: 24935
SEC CIK: 0001638474

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813	Director	June 28, 2022	June 30, 2022
Kymera Therapeutics, Inc.KYMR · Entity 3545	Director	June 24, 2026	June 25, 2026
Spyre Therapeutics, Inc.SYRE · Entity 2649	Director	August 07, 2026	August 11, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Dianthus Therapeutics, Inc. /DE/

Report date June 28, 2022 · Filed June 30, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 · Expires 2032-06-27	Direct	20,000	Reported balance After 2022-06-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-28 · Grant · Acquired 20,000 · Balance 20,000 F1: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 28, 2023 or (b) the next annual meeting of the Issuer's stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 28, 2023 or (b) the next annual meeting of the Issuer's stockholders.

Kymera Therapeutics, Inc.

Report date June 24, 2026 · Filed June 25, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.87 · Expires 2036-06-23	Direct	6,068	Reported balance After 2026-06-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-24 · Grant · Acquired 6,068 · Balance 6,068 F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.

Spyre Therapeutics, Inc.

Report date August 07, 2026 · Filed August 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2026-08-07 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-08-07 · Exercise / conversion · Acquired 5,000 · Balance 5,000 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. Row 2 · 2026-08-07 · Sale · Disposed 5,000 · Balance 0 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.59 to $105.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
Common StockSEC Table I · non-derivative	IndirectBy Sessions LLC	19,360	Reported balance After 2026-08-07 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2026-08-07 · Sale · Disposed 8,000 · Balance 19,360 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.52 to $105.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Common StockSEC Table I · non-derivative	IndirectBy Sessions LLC	9,360	Reported balance After 2026-08-07 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2026-08-07 · Sale · Disposed 10,000 · Balance 9,360 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.60 to $106.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.39 · Expires 2033-11-22	Direct	45,000	Reported balance After 2026-08-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-08-07 · Exercise / conversion · Disposed 5,000 · Balance 45,000 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F5: This option represents a right to purchase 50,000 shares of the Issuer's common stock, which vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.

F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.59 to $105.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.52 to $105.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.60 to $106.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F5: This option represents a right to purchase 50,000 shares of the Issuer's common stock, which vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Blueprint Medicines Corp

Report date July 17, 2025 · Filed July 21, 2025

Section 16 reporting ended · disclosed 2025-07-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2025-07-17 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2025-07-17 · Disposition to issuer · Disposed 5,777 · Balance 144,755 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration. Row 2 · 2025-07-17 · Other · Disposed 144,755 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.05	Direct	Reported balance After 2025-07-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-07-17 · Disposition to issuer · Disposed 92,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.44	Direct	Reported balance After 2025-07-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-07-17 · Disposition to issuer · Disposed 170,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $86.60	Direct	Reported balance After 2025-07-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-07-17 · Disposition to issuer · Disposed 110,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $54.13	Direct	Reported balance After 2025-07-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-07-17 · Disposition to issuer · Disposed 90,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.13	Direct	Reported balance After 2025-07-17 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-07-17 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.31	Direct	Reported balance After 2025-07-17 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-07-17 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.66	Direct	Reported balance After 2025-07-17 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-07-17 · Disposition to issuer · Disposed 5,300 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.14	Direct	Reported balance After 2025-07-17 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-07-17 · Disposition to issuer · Disposed 4,570 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 19, 2021 Filed Aug 23, 2021 16:24 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $1.87	$0.00	Disclosure SEC source: 0001179110-21-008347 · edgar.xml · derivative · entry 6 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,903 Underlying: Common Stock · 7,500 shares Expires 2024-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on January 11, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: This option was granted on July 30, 2014 and is fully vested as of the date hereof. Read SEC document
August 19, 2021 Filed Aug 23, 2021 16:24 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	17,500	$0.00 Strike: $15.01	$0.00	Disclosure SEC source: 0001179110-21-008347 · edgar.xml · derivative · entry 5 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 17,500 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on January 11, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: This option was granted on February 3, 2016 and is fully vested as of the date hereof. Read SEC document
August 19, 2021 Filed Aug 23, 2021 16:24 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	10,185	$92.21	$939,158.85	Disclosure SEC source: 0001179110-21-008347 · edgar.xml · nonDerivative · entry 4 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,448 F1 · kind: Effected pursuant to a trading plan adopted on January 11, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.72 to $92.51 per share. Read SEC document
August 19, 2021 Filed Aug 23, 2021 16:24 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	14,815	$93.01	$1,377,943.15	Disclosure SEC source: 0001179110-21-008347 · edgar.xml · nonDerivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,633 F1 · kind: Effected pursuant to a trading plan adopted on January 11, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.52 to $93.51 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document
August 19, 2021 Filed Aug 23, 2021 16:24 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	17,500	$15.01	$262,675.00	Disclosure SEC source: 0001179110-21-008347 · edgar.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on January 11, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
August 19, 2021 Filed Aug 23, 2021 16:24 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	7,500	$1.87	$14,025.00	Disclosure SEC source: 0001179110-21-008347 · edgar.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on January 11, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
June 16, 2021 Filed Jun 17, 2021 20:44 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	GrantStock Option (Right to Buy) · Derivative	20,063	$0.00 Strike: $49.10	$0.00	Disclosure SEC source: 0000899243-21-024432 · doc4.xml · derivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,063 Underlying: Common Stock · 20,063 shares Expires 2031-06-15 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 16, 2022 and (ii) the date of the next annual meeting of the Issuer's stockholders. Read SEC document
June 01, 2021 Filed Jun 3, 2021 22:27 UTC	Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813	GrantStock Option (Right to Buy) · Derivative	18,188	$0.00 Strike: $12.91	$0.00	Disclosure SEC source: 0000899243-21-021835 · doc4.xml · derivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2031-05-31 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 1, 2022 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document
May 12, 2021 Filed May 14, 2021 18:02 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $1.87	$0.00	Disclosure SEC source: 0001179110-21-005387 · edgar.xml · derivative · entry 7 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,403 Underlying: Common Stock · 7,500 shares Expires 2024-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on January 11, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · derivative.exercise_date: This option was granted on July 30, 2014 and is fully vested as of the date hereof. Read SEC document
May 12, 2021 Filed May 14, 2021 18:02 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	17,500	$0.00 Strike: $15.01	$0.00	Disclosure SEC source: 0001179110-21-005387 · edgar.xml · derivative · entry 6 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,500 Underlying: Common Stock · 17,500 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on January 11, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: This option was granted on February 3, 2016 and is fully vested as of the date hereof. Read SEC document
May 12, 2021 Filed May 14, 2021 18:02 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	2,953	$91.89	$271,351.17	Disclosure SEC source: 0001179110-21-005387 · edgar.xml · nonDerivative · entry 5 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,448 F1 · kind: Effected pursuant to a trading plan adopted on January 11, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.73 to $92.06 per share. Read SEC document
May 12, 2021 Filed May 14, 2021 18:02 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	16,383	$92.62	$1,517,393.46	Disclosure SEC source: 0001179110-21-005387 · edgar.xml · nonDerivative · entry 4 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,401 F1 · kind: Effected pursuant to a trading plan adopted on January 11, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.08 to $93.06 per share. Read SEC document
May 12, 2021 Filed May 14, 2021 18:02 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	5,664	$93.33	$528,621.12	Disclosure SEC source: 0001179110-21-005387 · edgar.xml · nonDerivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,784 F1 · kind: Effected pursuant to a trading plan adopted on January 11, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.07 to $94.06 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4. Read SEC document
May 12, 2021 Filed May 14, 2021 18:02 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	17,500	$15.01	$262,675.00	Disclosure SEC source: 0001179110-21-005387 · edgar.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on January 11, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
May 12, 2021 Filed May 14, 2021 18:02 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	7,500	$1.87	$14,025.00	Disclosure SEC source: 0001179110-21-005387 · edgar.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on January 11, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
March 04, 2021 Filed Mar 5, 2021 17:48 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $8.80	$0.00	Disclosure SEC source: 0001179110-21-003003 · edgar.xml · derivative · entry 10 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,170 Underlying: Common Stock · 10,000 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · derivative.exercise_date: This option was granted on February 10, 2015 and is fully vested as of the date hereof. Read SEC document
March 04, 2021 Filed Mar 5, 2021 17:48 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	8,417	$86.61	$728,996.37	Disclosure SEC source: 0001179110-21-003003 · edgar.xml · nonDerivative · entry 9 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,448 F6 · kind: This sale represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document
March 04, 2021 Filed Mar 5, 2021 17:48 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	569	$88.63	$50,430.47	Disclosure SEC source: 0001179110-21-003003 · edgar.xml · nonDerivative · entry 8 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,865 F6 · kind: This sale represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.34 to $89.15 per share. Read SEC document
March 04, 2021 Filed Mar 5, 2021 17:48 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	100	$86.61	$8,661.00	Disclosure SEC source: 0001179110-21-003003 · edgar.xml · nonDerivative · entry 7 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,434 F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
March 04, 2021 Filed Mar 5, 2021 17:48 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	100	$89.18	$8,918.00	Disclosure SEC source: 0001179110-21-003003 · edgar.xml · nonDerivative · entry 6 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,534 F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
March 04, 2021 Filed Mar 5, 2021 17:48 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	404	$90.18	$36,432.72	Disclosure SEC source: 0001179110-21-003003 · edgar.xml · nonDerivative · entry 5 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,634 F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.02 to $90.27 per share. Read SEC document
March 04, 2021 Filed Mar 5, 2021 17:48 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	3,000	$90.99	$272,970.00	Disclosure SEC source: 0001179110-21-003003 · edgar.xml · nonDerivative · entry 4 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,038 F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.37 to $91.30 per share. Read SEC document
March 04, 2021 Filed Mar 5, 2021 17:48 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	5,296	$91.78	$486,066.88	Disclosure SEC source: 0001179110-21-003003 · edgar.xml · nonDerivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,038 F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.31 to $92.30 per share. Read SEC document
March 04, 2021 Filed Mar 5, 2021 17:48 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	1,100	$93.21	$102,531.00	Disclosure SEC source: 0001179110-21-003003 · edgar.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,334 F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.69 to $93.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) and footnote (7) to this Form 4. Read SEC document
March 04, 2021 Filed Mar 5, 2021 17:48 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	10,000	$8.80	$88,000.00	Disclosure SEC source: 0001179110-21-003003 · edgar.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
March 01, 2021 Filed Mar 3, 2021 16:26 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantStock Option (Right to Buy) · Derivative	80,000	$0.00 Strike: $100.13	$0.00	Disclosure SEC source: 0001179110-21-002668 · edgar.xml · derivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-03-01 F2 · derivative.exercise_date: This option vests with respect to 1/48th of the shares underlying the option on April 1, 2021 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
March 01, 2021 Filed Mar 3, 2021 16:26 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantCommon Stock	40,000	$0.00	$0.00	Disclosure SEC source: 0001179110-21-002668 · edgar.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,434 F1 · balance_after: The reported transaction involved the Reporting Person's receipt of a grant of 40,000 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan. Read SEC document
December 14, 2020 Filed Dec 16, 2020 16:04 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $8.80	$0.00	Disclosure SEC source: 0001179110-20-011990 · edgar.xml · derivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,170 Underlying: Common Stock · 5,000 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · derivative.exercise_date: This option was granted on February 10, 2015 and is fully vested as of the date hereof. Read SEC document
December 14, 2020 Filed Dec 16, 2020 16:04 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	5,000	$119.18	$595,900.00	Disclosure SEC source: 0001179110-20-011990 · edgar.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,434 F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.00 to $119.59 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 14, 2020 Filed Dec 16, 2020 16:04 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	5,000	$8.80	$44,000.00	Disclosure SEC source: 0001179110-20-011990 · edgar.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
November 16, 2020 Filed Nov 18, 2020 16:22 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $8.80	$0.00	Disclosure SEC source: 0001179110-20-011197 · edgar.xml · derivative · entry 6 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,170 Underlying: Common Stock · 20,000 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · derivative.exercise_date: This option was granted on February 10, 2015 and is fully vested as of the date hereof. Read SEC document
November 16, 2020 Filed Nov 18, 2020 16:22 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	6,521	$97.61	$636,514.81	Disclosure SEC source: 0001179110-20-011197 · edgar.xml · nonDerivative · entry 5 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,434 F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.15 to $97.89 per share. Read SEC document
November 16, 2020 Filed Nov 18, 2020 16:22 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	4,483	$98.13	$439,916.79	Disclosure SEC source: 0001179110-20-011197 · edgar.xml · nonDerivative · entry 4 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,955 F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.90 to $98.89 per share. Read SEC document
November 16, 2020 Filed Nov 18, 2020 16:22 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	4,869	$99.55	$484,708.95	Disclosure SEC source: 0001179110-20-011197 · edgar.xml · nonDerivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,438 F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.02 to $99.92 per share. Read SEC document
November 16, 2020 Filed Nov 18, 2020 16:22 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	4,127	$100.11	$413,153.97	Disclosure SEC source: 0001179110-20-011197 · edgar.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,307 F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.93 to $100.92 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2 to 5 to this form 4. Read SEC document
November 16, 2020 Filed Nov 18, 2020 16:22 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	20,000	$8.80	$176,000.00	Disclosure SEC source: 0001179110-20-011197 · edgar.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
October 07, 2020 Filed Oct 9, 2020 16:05 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $8.80	$0.00	Disclosure SEC source: 0001179110-20-010369 · edgar.xml · derivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,170 Underlying: Common Stock · 5,000 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · derivative.exercise_date: This option was granted on February 10, 2015 and is fully vested as of the hereof. Read SEC document
October 07, 2020 Filed Oct 9, 2020 16:05 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	5,000	$99.17	$495,850.00	Disclosure SEC source: 0001179110-20-010369 · edgar.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,434 F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.00 to $99.465 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
October 07, 2020 Filed Oct 9, 2020 16:05 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	5,000	$8.80	$44,000.00	Disclosure SEC source: 0001179110-20-010369 · edgar.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
August 20, 2020 Filed Aug 21, 2020 22:27 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	GrantStock Option (Right to Buy) · Derivative	40,127	$0.00 Strike: $20.00	$0.00	Disclosure SEC source: 0000899243-20-023238 · doc4.xml · derivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,127 Underlying: Common Stock · 40,127 shares Expires 2030-08-19 F1 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years commencing on the date of the Registration Statement Effectiveness. Read SEC document
August 19, 2020 Filed Aug 21, 2020 16:22 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $8.80	$0.00	Disclosure SEC source: 0001179110-20-009220 · edgar.xml · derivative · entry 4 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,170 Underlying: Common Stock · 20,000 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: This option was granted on February 10, 2015 and is fully vested. Read SEC document
August 19, 2020 Filed Aug 21, 2020 16:22 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	8,597	$74.60	$641,336.20	Disclosure SEC source: 0001179110-20-009220 · edgar.xml · nonDerivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,434 F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.00 to $74.99 per share. Read SEC document
August 19, 2020 Filed Aug 21, 2020 16:22 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	11,403	$75.34	$859,102.02	Disclosure SEC source: 0001179110-20-009220 · edgar.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,031 F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.94 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document
August 19, 2020 Filed Aug 21, 2020 16:22 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	20,000	$8.80	$176,000.00	Disclosure SEC source: 0001179110-20-009220 · edgar.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
June 05, 2020 Filed Jun 9, 2020 20:21 UTC	Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813	GrantStock Option (Right to Buy) · Derivative	18,188	$0.00 Strike: $9.99	$0.00	Disclosure SEC source: 0000899243-20-015789 · doc4.xml · derivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2030-06-04 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document
May 12, 2020 Filed May 14, 2020 16:38 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $8.80	$0.00	Disclosure SEC source: 0001179110-20-005993 · edgar.xml · derivative · entry 5 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,170 Underlying: Common Stock · 20,000 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: This option was granted on February 10, 2015 and is fully vested. Read SEC document
May 12, 2020 Filed May 14, 2020 16:38 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	9,568	$63.93	$611,682.24	Disclosure SEC source: 0001179110-20-005993 · edgar.xml · nonDerivative · entry 4 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,434 F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.40 to $64.38 per share. Read SEC document
May 12, 2020 Filed May 14, 2020 16:38 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	4,282	$64.75	$277,259.50	Disclosure SEC source: 0001179110-20-005993 · edgar.xml · nonDerivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,002 F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.40 to $65.38 per share. Read SEC document
May 12, 2020 Filed May 14, 2020 16:38 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	6,150	$65.77	$404,485.50	Disclosure SEC source: 0001179110-20-005993 · edgar.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,284 F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.41 to $66.28 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4. Read SEC document
May 12, 2020 Filed May 14, 2020 16:38 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	20,000	$8.80	$176,000.00	Disclosure SEC source: 0001179110-20-005993 · edgar.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.